In vivo labeling of BMI1+ CSCs revealed that MYCi975 efficiently eliminated BMI1+ CSCs in recurrent HNSCC, while BMI1+ CSCs remained in recurrent HNSCC treated with cisplatin (Figure S7J and S7K). Here, BMI1 is linked to head and neck squamous cell carcinoma.